Alamar Biosciences reports company developments tied to its Precision Proteomics platform, NULISA technology, and commercialization of instruments, consumables, assays, panels, and services for protein biomarker analysis. Recurring updates include financial results, product launches such as NULISAseq and NULISAqpcr offerings, platform adoption among research and biopharma customers, and public-company milestones following its Nasdaq listing.
Company news also covers healthcare conference participation and corporate updates related to the business model for proteomics tools used in disease research and early-detection applications.
Alamar Biosciences (Nasdaq: ALMR) announced that its NULISA™ precision proteomics platform will appear in more than 140 posters and sessions at the Alzheimer’s Association International Conference (AAIC) 2026 in London, July 12‑15, reflecting broad research use in Alzheimer’s and related dementias.
The company will host a workshop, “Beyond p-tau217: Expanding Alzheimer's Insights with Multiplex Protein Profiling,” on July 14, 1:20–2:00 PM BST, highlighting eMTBR-Tau and BD-pTau217 assays, their use alongside over 220 disease-related proteins, and applications across presymptomatic to diagnosed populations.
Alamar Biosciences (Nasdaq: ALMR) launched the first commercial eMTBR-Tau blood immunoassay, a non-invasive test reflecting tau tangle pathology in Alzheimer’s disease. The assay is available within the NULISAseq Neuro 220 multiplexed panel, deployable on all ARGO HT instruments, and as a single-plex assay via the Technology Access Program.
The eMTBR-Tau assay targets an MTBR fragment generated at site 256, offers attomolar sensitivity, and can be run alongside other neurodegeneration and neuroinflammation biomarkers from a low-volume sample. According to Alamar, data on analytical performance and clinical findings will be presented at an AAIC 2026 workshop in London.
Alamar Biosciences (Nasdaq: ALMR) reported Q1 2026 revenue of $26.0 million, a 99% increase year-over-year, driven by instrument placements and consumable pull-through. Gross margin improved to 56% from 49% due to higher volumes and favorable product mix.
Operating loss was $12.3 million and net loss was $21.3 million, which included an $8.6 million remeasurement of convertible notes. After quarter end, the company completed an IPO, generating $197.8 million net proceeds, and held $69.5 million in cash and equivalents as of March 31, 2026.
Alamar Biosciences (Nasdaq: ALMR) will present at the BofA Securities 2026 Healthcare Conference in Las Vegas on Tuesday, May 12, 2026 at 3:40 p.m. PT / 6:40 p.m. ET. A live and archived webcast will be available in the Investors section at investors.alamarbio.com.
Alamar Biosciences (NASDAQ:ALMR) completed its NASDAQ listing on April 17, 2026, issuing shares at $17 and opening at $22.6, implying a market capitalization of approximately $1.5 billion. The company commercializes NULISA™ and ARGO™ HT; by end-2025 ARGO HT had >100 installed systems serving 300+ customers in 25 countries.
Qiming Venture Partners held about 19.2% pre-IPO and backed Alamar through Series A–C financings.